Identification of Genetic Polymorphic Variants Associated With Somatosensory Disorders and Methods of Using the Same

• US 20090253585A1
• Filed: 11/29/2006
• Published: 10/08/2009
• Est. Priority Date: 11/30/2005
• Status: Abandoned Application

• Current Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Original Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Inventors: Diatchenko, Luda, Maixner, William
• Application Number:
  US12/085,785
• Publication Number:
  US 20090253585A1
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/172 Haplotypes
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Methods of predicting effective pharmacological therapies for a subject afflicted with a somatosensory disorder by determining a genotype of the subject with or without determination of psychosocial and/or neurological assessments of the subject are provided. Methods of predicting susceptibility of a subject to develop somatosensory disorders by determining a genotype of the subject with or without determination of psychosocial and/or neurological assessments of the subject are further provided.

Claims

1. A method of predicting susceptibility of a subject to develop a somatosensory disorder, comprising:

(a) determining a genotype of the subject with respect to one or more of genes selected from Table 1; and

(b) comparing the genotype of the subject with one or more of reference genotypes associated with susceptibility to develop the somatosensory disorder, whereby susceptibility of the subject to develop the somatosensory disorder is predicted.

2. The method of claim 1, wherein determining the genotype of the subject comprises:

(i) identifying at least one haplotype from each of the one or more genes selected from Table 1;

(ii) identifying at least one polymorphism unique to at least one haplotype from each of the one or more genes selected from Table 1;

(iii) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one polymorphism unique to each of the one or more genes selected from Table 1;

(iv) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one of the one or more genes selected from Table 1;

or

(v) combinations thereof.

3. The method of claim 2, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from Table 2.

4. The method of claim 2, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from Table 3.

5. The method of claim 1, wherein the somatosensory disorder is selected from the group consisting of chronic pain conditions, fibromyalgia syndrome, tension headache, migraine headache, phantom limb sensations, irritable bowel syndrome, chronic lower back pain, chronic fatigue, multiple chemical sensitivities, temporomandibular joint disorder, post-traumatic stress disorder, chronic idiopathic pelvic pain, Gulf War Syndrome, vulvar vestibulitis, osteoarthritis, rheumatoid arthritis, angina pectoris, postoperative pain, and neuropathic pain.

6. The method of claim 1, wherein predicting susceptibility of a subject to develop a somatosensory disorder comprises predicting a pain response in the subject.

7. The method of claim 1, wherein predicting susceptibility of a subject to develop a somatosensory disorder comprises predicting somatization in the subject.

8. A method of predicting susceptibility of a subject to develop a somatosensory disorder, comprising:

(a) determining a genotype of the subject with respect to one or more genes selected from the group consisting of ADRB2, ADRB3, and COMT in combination with at least one gene selected from Table 1; and

(b) comparing the genotype of the subject with one or more reference genotypes associated with susceptibility to develop the somatosensory disorder, whereby susceptibility of the subject to develop the somatosensory disorder is predicted.

9. The method of claim 8, wherein determining the genotype of the subject comprises:

(i) identifying at least one haplotype of ADRB2, ADRB3, COMT or combinations thereof and the at least one gene selected from Table 1;

(ii) identifying at least one polymorphism unique to at least one haplotype of ADRB2, ADRB3, COMT, or combinations thereof and the at least one gene selected from Table 1;

(iii) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one polymorphism unique to at least one haplotype of ADRB2, ADRB3, COMT, or combinations thereof and the at least one gene selected from Table 1;

(iv) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one haplotype of ADRB2, ADRB3, COMT, or combinations thereof and the at least one gene selected from Table 1;

or

(v) combinations thereof.

10. The method of claim 9, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from ADRB2, ADRB3, COMT or Table 2.

11. The method of claim 9, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from ADRB2, ADRB3, COMT or Table 3.

12. The method of claim 8, wherein the somatosensory disorder is selected from the group consisting of chronic pain conditions, fibromyalgia syndrome, tension headache, migraine headache, phantom limb sensations, irritable bowel syndrome, chronic lower back pain, chronic fatigue, multiple chemical sensitivities, temporomandibular joint disorder, post-traumatic stress disorder, chronic idiopathic pelvic pain, Gulf War Syndrome, vulvar vestibulitis, osteoarthritis, rheumatoid arthritis, angina pectoris, postoperative pain, and neuropathic pain.

13. The method of claim 8, wherein predicting susceptibility of a subject to develop a somatosensory disorder comprises predicting a pain response in the subject.

14. The method of claim 8, wherein predicting susceptibility of a subject to develop a somatosensory disorder comprises predicting somatization in the subject.

22. The method of claim 9, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from Table 6.

15. A method of predicting susceptibility of a subject to develop a somatosensory disorder, comprising:

(a) determining a psychosocial assessment, a neurological assessment, or both, of a subject;

(b) determining a genotype of the subject with respect to one or more genes selected from Table 4; and

(c) predicting susceptibility of the subject to develop a somatosensory disorder based on the determined psychosocial assessment, neurological assessment, or both, and the determined genotype of the subject.

16. The method of claim 15, wherein determining the psychosocial assessment of the subject comprises testing the subject with at least one psychosocial questionnaire comprising one or more questions that each assess anxiety, depression, somatization, stress, cognition, pain perception, or combinations thereof of the subject.

17. The method of claim 16, wherein the at least one psychosocial questionnaire is selected from the group consisting of Eysenck Personality Questionnaire, Life Experiences Survey, Perceived Stress Scale, State-Trait Anxiety Inventory (STAI) Form Y-2, STAI Form Y-1, Pittsburgh Sleep Quality Index, Kohn Reactivity Scale, Pennebaker Inventory for Limbic Languidness, Short Form 12 Health Survey v2, SF-36, Pain Catastrophizing Scale, In vivo Coping Questionnaire, Coping Strategies Questionnaire-Rev, Lifetime Stressor List &

Post-Traumatic Stress Disorder (PTSTD) Checklist for Civilians, Multidimensional Pain Inventory v3, Comprehensive Pain &

Symptom Questionnaire, Symptom Checklist-90-R(SCL-90R), Brief Symptom Inventory (BSI), Beck Depression Inventory (BDI), Profile of Mood States Bi-polar, Pain Intensity Measures, and Pain Unpleasantness Measures.

18. The method of claim 15, wherein determining the neurological state of the subject comprises testing the subject with at least one neurological testing apparatus.

19. The method of claim 16, wherein the neurological testing apparatus is selected from the group consisting of Thermal Pain Delivery and Measurement Devices, Mechanical Pain Delivery and Measurement Devices, Ischemic Pain Delivery and Measurement Devices, Chemical Pain Delivery and Measurement Devices, Electrical Pain Delivery and Measurement Devices, Vibrotactile Delivery and Measurement Devices, Blood Pressure Measuring Devices, Heart Rate Measuring Devices, Heart Rate Variability Measuring Devices, Baroreceptor Monitoring Devices, Cardiac Output Monitoring Devices, Blood Flow Monitoring Devices, and Skin Temperature Measuring Devices.

20. The method of claim 15, wherein determining the genotype of the subject comprises:

(i) identifying at least one haplotype of the one or more genes selected from Table 4;

(ii) identifying at least one polymorphism unique to at least one haplotype of the one or more genes selected from Table 4;

(iii) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one polymorphism unique to at least one haplotype of the one or more genes selected from Table 4;

(iv) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one haplotype of the one or more genes selected from Table 4;

or

(v) combinations thereof.

21. The method of claim 20, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from Table 5.

23. The method of claim 15, wherein the somatosensory disorder is selected from the group consisting of chronic pain conditions, fibromyalgia syndrome, tension headache, migraine headache, phantom limb sensations, irritable bowel syndrome, chronic lower back pain, chronic fatigue, multiple chemical sensitivities, temporomandibular joint disorder, post-traumatic stress disorder, chronic idiopathic pelvic pain, Gulf War Syndrome, vulvar vestibulitis, osteoarthritis, rheumatoid arthritis, angina pectoris, postoperative pain, and neuropathic pain.

24. The method of claim 15, wherein predicting susceptibility of a subject to develop a somatosensory disorder comprises predicting a pain response in the subject.

25. The method of claim 15, wherein predicting susceptibility of a subject to develop a somatosensory disorder comprises predicting somatization in the subject.

26. A method of selecting a therapy, predicting a response to a therapy, or both, for a subject having a somatosensory disorder, comprising:

(a) determining a genotype of the subject with respect to one or more genes selected from Table 1; and

(b) selecting a therapy, predicting a response to a therapy, or both, based on the determined genotype of the subject.

27. The method of claim 26, wherein determining the genotype of the subject comprises:

(i) identifying at least one haplotype from each of the one or more genes selected from Table 1;

(ii) identifying at least one polymorphism unique to at least one haplotype from each of the one or more genes selected from Table 1;

(iii) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one polymorphism unique to each of the one or more genes selected from Table 1;

(iv) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one of the one or more genes selected from Table 1;

or

(v) combinations thereof.

28. The method of claim 27, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from Table 2.

29. The method of claim 27, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from Table 3.

30. The method of claim 26, wherein the therapy is selected from the group consisting of a pharmacological therapy, a behavioral therapy, a psychotherapy, a surgical therapy, and combinations thereof.

31. The method of claim 30, wherein the subject is undergoing or recovering from a surgical therapy and the method comprises selecting a pain management therapy, predicting a response to a pain management therapy, or both based on the determined genotype of the subject.

32. The method of claim 26, wherein the somatosensory disorder is selected from the group consisting of chronic pain conditions, fibromyalgia syndrome, tension headache, migraine headache, phantom limb sensations, irritable bowel syndrome, chronic lower back pain, chronic fatigue, multiple chemical sensitivities, temporomandibular joint disorder, post-traumatic stress disorder, chronic idiopathic pelvic pain, Gulf War Syndrome, vulvar vestibulitis, osteoarthritis, rheumatoid arthritis, angina pectoris, postoperative pain, and neuropathic pain.

33. A method of selecting a therapy, predicting a response to a therapy, or both, for a subject having a somatosensory disorder, comprising:

(a) determining a genotype of the subject with respect to one or more genes selected from the group consisting of ADRB2, ADRB3, and COMT in combination with at least one gene selected from Table 1; and

(b) selecting a therapy based on the determined genotype of the subject.

34. The method of claim 33, wherein determining the genotype of the subject comprises:

(i) identifying at least one haplotype of ADRB2, ADRB3, COMT or combinations thereof and the at least one gene selected from Table 1;

(ii) identifying at least one polymorphism unique to at least one haplotype of ADRB2, ADRB3, COMT, or combinations thereof and the at least one gene selected from Table 1;

(iii) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one polymorphism unique to at least one haplotype of ADRB2, ADRB3, COMT, or combinations thereof and the at least one gene selected from Table 1;

(iv) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one haplotype of ADRB2, ADRB3, COMT, or combinations thereof and the at least one gene selected from Table 1;

or

(v) combinations thereof.

35. The method of claim 34, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from ADRB2, ADRB3, COMT or Table 2.

36. The method of claim 34, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from ADRB2, ADRB3, COMT or Table 3.

37. The method of claim 33, wherein the therapy is selected from the group consisting of a pharmacological therapy, a behavioral therapy, a psychotherapy, a surgical therapy, and combinations thereof.

38. The method of claim 37, wherein the subject is undergoing or recovering from a surgical therapy and the method comprises selecting a pain management therapy, predicting a response to a pain management therapy, or both based on the determined genotype of the subject.

39. The method of claim 33, wherein the somatosensory disorder is selected from the group consisting of chronic pain conditions, fibromyalgia syndrome, tension headache, migraine headache, phantom limb sensations, irritable bowel syndrome, chronic lower back pain, chronic fatigue, multiple chemical sensitivities, temporomandibular joint disorder, post-traumatic stress disorder, chronic idiopathic pelvic pain, Gulf War Syndrome, vulvar vestibulitis, osteoarthritis, rheumatoid arthritis, angina pectoris, postoperative pain, and neuropathic pain.

40. A method of selecting a therapy, predicting a response to a therapy, or both for a subject having a somatosensory disorder, comprising:

(a) determining a psychosocial assessment, a neurological assessment, or both, of a subject

(b) determining a genotype of the subject with respect to one or more genes selected from Table 4; and

(c) selecting a therapy, predicting a response to a therapy, or both for the subject having the somatosensory disorder based on the determined psychosocial assessment, neurological assessment, or both, and the determined genotype of the subject.

41. The method of claim 40, wherein determining the psychosocial assessment of the subject comprises testing the subject with at least one psychosocial questionnaire comprising one or more questions that each assess anxiety, depression, somatization, stress, cognition, pain perception, or combinations thereof of the subject.

42. The method of claim 41, wherein the at least one psychosocial questionnaire is selected from the group consisting of Eysenck Personality Questionnaire, Life Experiences Survey, Perceived Stress Scale, State-Trait Anxiety Inventory (STAI) Form Y-2, STAI Form Y-1, Pittsburgh Sleep Quality Index, Kohn Reactivity Scale, Pennebaker Inventory for Limbic Languidness, Short Form 12 Health Survey v2, SF-36, Pain Catastrophizing Scale, In vivo Coping Questionnaire, Coping Strategies Questionnaire-Rev, Lifetime Stressor List &

Post-Traumatic Stress Disorder (PTSTD) Checklist for Civilians, Multidimensional Pain Inventory v3, Comprehensive Pain &

Symptom Questionnaire, Symptom Checklist-90-R(SCL-90R), Brief Symptom Inventory (BSI), Beck Depression Inventory (BDI), Profile of Mood States Bi-polar, Pain Intensity Measures, and Pain Unpleasantness Measures.

43. The method of claim 40, wherein determining the neurological state of the subject comprises testing the subject with at least one neurological testing apparatus.

44. The method of claim 43, wherein the neurological testing apparatus is selected from the group consisting of Thermal Pain Delivery and Measurement Devices, Mechanical Pain Delivery and Measurement Devices, Ischemic Pain Delivery and Measurement Devices, Chemical Pain Delivery and Measurement Devices, Electrical Pain Delivery and Measurement Devices, Vibrotactile Delivery and Measurement Devices, Blood Pressure Measuring Devices, Heart Rate Measuring Devices, Heart Rate Variability Measuring Devices, Baroreceptor Monitoring Devices, Cardiac Output Monitoring Devices, Blood Flow Monitoring Devices, and Skin Temperature Measuring Devices.

45. The method of claim 40, wherein determining the genotype of the subject comprises:

(i) identifying at least one haplotype of the one or more genes selected from Table 4;

(ii) identifying at least one polymorphism unique to at least one haplotype of the one or more genes selected from Table 4;

(iii) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one polymorphism unique to at least one haplotype of the one or more genes selected from Table 4;

(iv) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one haplotype of the one or more genes selected from Table 4;

or

(v) combinations thereof.

46. The method of claim 45, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from Table 5.

47. The method of claim 45, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from Table 6.

48. The method of claim 40, wherein the therapy is selected from the group consisting of a pharmacological therapy, a behavioral therapy, a psychotherapy, a surgical therapy, and combinations thereof.

49. The method of claim 48, wherein the subject is undergoing or recovering from a surgical therapy and the method comprises selecting a pain management therapy, predicting a response to a pain management therapy, or both based on the determined genotype of the subject.

50. The method of claim 40, wherein the somatosensory disorder is selected from the group consisting of chronic pain conditions, fibromyalgia syndrome, tension headache, migraine headache, phantom limb sensations, irritable bowel syndrome, chronic lower back pain, chronic fatigue, multiple chemical sensitivities, temporomandibular joint disorder, post-traumatic stress disorder, chronic idiopathic pelvic pain, Gulf War Syndrome, vulvar vestibulitis, osteoarthritis, rheumatoid arthritis, angina pectoris, postoperative pain, and neuropathic pain.

51. A method of classifying a somatosensory disorder afflicting a subject, comprising:

(a) determining a genotype of the subject with respect to one or more genes selected from Table 1; and

(b) classifying the somatosensory disorder into a genetic subclass somatosensory disorder based on the determined genotype of the subject.

52. The method of claim 51, wherein determining the genotype of the subject comprises:

(i) identifying at least one haplotype from each of the one or more genes selected from Table 1;

(ii) identifying at least one polymorphism unique to at least one haplotype from each of the one or more genes selected from Table 1;

(iii) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one polymorphism unique to each of the one or more genes selected from Table 1;

(iv) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one of the one or more genes selected from Table 1;

or

(v) combinations thereof.

53. The method of claim 52, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from Table 2.

54. The method of claim 52, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from Table 3.

55. The method of claim 51, wherein classifying the somatosensory disorder into the genetic subclass somatosensory disorder is utilized to select an effective therapy for use in treating the genetic subclass somatosensory disorder.

56. The method of claim 51, wherein the somatosensory disorder is selected from the group consisting of chronic pain conditions, fibromyalgia syndrome, tension headache, migraine headache, phantom limb sensations, irritable bowel syndrome, chronic lower back pain, chronic fatigue, multiple chemical sensitivities, temporomandibular joint disorder, post-traumatic stress disorder, chronic idiopathic pelvic pain, Gulf War Syndrome, vulvar vestibulitis, osteoarthritis, rheumatoid arthritis, angina pectoris, postoperative pain, and neuropathic pain.

57. A method of classifying a somatosensory disorder afflicting a subject, comprising:

(a) determining a genotype of the subject with respect to one or more genes selected from the group consisting of ADRB2, ADRB3, and COMT in combination with at least one gene selected from Table 1; and

(b) classifying the somatosensory disorder into a genetic subclass somatosensory disorder based on the determined genotype of the subject.

58. The method of claim 57, wherein determining the genotype of the subject comprises:

(i) identifying at least one haplotype of ADRB2, ADRB3, COMT or combinations thereof and the at least one gene selected from Table 1;

(ii) identifying at least one polymorphism unique to at least one haplotype of ADRB2, ADRB3, COMT, or combinations thereof and the at least one gene selected from Table 1;

(iii) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one polymorphism unique to at least one haplotype of ADRB2, ADRB3, COMT, or combinations thereof and the at least one gene selected from Table 1;

(iv) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one haplotype of ADRB2, ADRB3, COMT, or combinations thereof and the at least one gene selected from Table 1;

or

(v) combinations thereof.

59. The method of claim 58, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from ADRB2, ADRB3, COMT or Table 2.

60. The method of claim 58, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from ADRB2, ADRB3, COMT or Table 3.

61. The method of claim 57, wherein classifying the somatosensory disorder into the genetic subclass somatosensory disorder is utilized to select an effective therapy for use in treating the genetic subclass somatosensory disorder.

62. The method of claim 57, wherein the somatosensory disorder is selected from the group consisting of chronic pain conditions, fibromyalgia syndrome, tension headache, migraine headache, phantom limb sensations, irritable bowel syndrome, chronic lower back pain, chronic fatigue, multiple chemical sensitivities, temporomandibular joint disorder, post-traumatic stress disorder, chronic idiopathic pelvic pain, Gulf War Syndrome, vulvar vestibulitis, osteoarthritis, rheumatoid arthritis, angina pectoris, postoperative pain, and neuropathic pain.

63. A method of classifying a somatosensory disorder afflicting a subject, comprising:

(a) determining a psychosocial assessment, a neurological assessment, or both, of a subject;

(b) determining a genotype of the subject with respect to one or more genes selected from Table 4; and

(c) classifying a somatosensory disorder afflicting the subject based on the determined psychosocial assessment, neurological assessment, or both, and the determined genotype of the subject.

64. The method of claim 63, wherein determining the psychosocial assessment of the subject comprises testing the subject with at least one psychosocial questionnaire comprising one or more questions that each assess anxiety, depression, somatization, stress, cognition, pain perception, or combinations thereof of the subject.

65. The method of claim 64, wherein the at least one psychosocial questionnaire is selected from the group consisting of Eysenck Personality Questionnaire, Life Experiences Survey, Perceived Stress Scale, State-Trait Anxiety Inventory (STAI) Form Y-2, STAI Form Y-1, Pittsburgh Sleep Quality Index, Kohn Reactivity Scale, Pennebaker Inventory for Limbic Languidness, Short Form 12 Health Survey v2, SF-36, Pain Catastrophizing Scale, In vivo Coping Questionnaire, Coping Strategies Questionnaire-Rev, Lifetime Stressor List &

Post-Traumatic Stress Disorder (PTSTD) Checklist for Civilians, Multidimensional Pain Inventory v3, Comprehensive Pain &

Symptom Questionnaire, Symptom Checklist-90-R(SCL-90R), Brief Symptom Inventory (BSI), Beck Depression Inventory (BDI), Profile of Mood States Bi-polar, Pain Intensity Measures, and Pain Unpleasantness Measures.

66. The method of claim 63, wherein determining the neurological state of the subject comprises testing the subject with at least one neurological testing apparatus.

67. The method of claim 66, wherein the neurological testing apparatus is selected from the group consisting of Thermal Pain Delivery and Measurement Devices, Mechanical Pain Delivery and Measurement Devices, Ischemic Pain Delivery and Measurement Devices, Chemical Pain Delivery and Measurement Devices, Electrical Pain Delivery and Measurement Devices, Vibrotactile Delivery and Measurement Devices, Blood Pressure Measuring Devices, Heart Rate Measuring Devices, Heart Rate Variability Measuring Devices, Baroreceptor Monitoring Devices, Cardiac Output Monitoring Devices, Blood Flow Monitoring Devices, and Skin Temperature Measuring Devices.

68. The method of claim 63, wherein determining the genotype of the subject comprises:

(i) identifying at least one haplotype of the one or more genes selected from Table 4;

(ii) identifying at least one polymorphism unique to at least one haplotype of the one or more genes selected from Table 4;

(iii) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one polymorphism unique to at least one haplotype of the one or more genes selected from Table 4;

(iv) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one haplotype of the one or more genes selected from Table 4;

or

(v) combinations thereof.

69. The method of claim 68, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from Table 5.

70. The method of claim 68, wherein the at least one polymorphism unique to the at least one haplotype is a single nucleotide polymorphism from Table 6.

71. The method of claim 63, wherein classifying the somatosensory disorder into the genetic subclass somatosensory disorder is utilized to select an effective therapy for use in treating the genetic subclass somatosensory disorder.

72. The method of claim 63, wherein the somatosensory disorder is selected from the group consisting of chronic pain conditions, fibromyalgia syndrome, tension headache, migraine headache, phantom limb sensations, irritable bowel syndrome, chronic lower back pain, chronic fatigue, multiple chemical sensitivities, temporomandibular joint disorder, post-traumatic stress disorder, chronic idiopathic pelvic pain, Gulf War Syndrome, vulvar vestibulitis, osteoarthritis, rheumatoid arthritis, angina pectoris, postoperative pain, and neuropathic pain.

73. A kit for determining a genotype of a subject that is associated with a somatosensory disorder, comprising:

(a) an array comprising a substrate and a plurality of polynucleotide probes arranged at specific locations on the substrate, wherein each probe has a binding affinity for a different polynucleotide sequence comprising a single nucleotide polymorphism selected from Table 5; and

(b) a set of instructions for using the array.

74. The kit of claim 73, wherein the substrate comprises a plurality of addresses, wherein each address is associated with at least one of the polynucleotide probes.

75. The kit of claim 73, wherein the polynucleotide sequence comprises a single nucleotide polymorphism selected from Table 6.

76. The kit of claim 73, wherein the set of instructions comprises instructions for interpreting results from the array.

77. A system, comprising:

(a) an array comprising a substrate and a plurality of polynucleotide probes arranged at specific locations on the substrate, wherein each probe has a binding affinity for a different polynucleotide sequence comprising a single nucleotide polymorphism selected from Table 5; and

(b) at least one neurological testing apparatus for determining a neurological assessment of the subject, at least one psychosocial questionnaire for determining a psychosocial assessment of the subject, or both the neurological testing apparatus and the psychosocial questionnaire.

78. The system of claim 77, comprising software for assessing results of the array, the neurological testing apparatus, and the psychosocial questionnaire.

79. The system of claim 78, wherein the software provides diagnostic information, therapeutic information, or both related to a somatosensory disorder about the subject.

80. The system of claim 77, wherein the substrate comprises a plurality of addresses, wherein each address is associated with at least one of the polynucleotide probes.

81. The system of claim 77, wherein the polynucleotide sequence comprises a single nucleotide polymorphism selected from Table 6.

82. The system of claim 77, wherein the at least one psychosocial questionnaire is selected from the group consisting of Eysenck Personality Questionnaire, Life Experiences Survey, Perceived Stress Scale, State-Trait Anxiety Inventory (STAI) Form Y-2, STAI Form Y-1, Pittsburgh Sleep Quality Index, Kohn Reactivity Scale, Pennebaker Inventory for Limbic Languidness, Short Form 12 Health Survey v2, SF-36, Pain Catastrophizing Scale, In vivo Coping Questionnaire, Coping Strategies Questionnaire-Rev, Lifetime Stressor List &

Post-Traumatic Stress Disorder (PTSTD) Checklist for Civilians, Multidimensional Pain Inventory v3, Comprehensive Pain &

Symptom Questionnaire, Symptom Checklist-90-R(SCL-90R), Brief Symptom Inventory (BSI), Beck Depression Inventory (BDI), Profile of Mood States Bi-polar, Pain Intensity Measures, and Pain Unpleasantness Measures.

83. The system of claim 77, wherein the neurological testing apparatus is selected from the group consisting of Thermal Pain Delivery and Measurement Devices, Mechanical Pain Delivery and Measurement Devices, Ischemic Pain Delivery and Measurement Devices, Chemical Pain Delivery and Measurement Devices, Electrical Pain Delivery and Measurement Devices, Vibrotactile Delivery and Measurement Devices, Blood Pressure Measuring Devices, Heart Rate Measuring Devices, Heart Rate Variability Measuring Devices, Baroreceptor Monitoring Devices, Cardiac Output Monitoring Devices, Blood Flow Monitoring Devices, and Skin Temperature Measuring Devices.